Dana CamAPS® FX And Pregnancy
Dana CamAPS® FX And The AiDAPT Pregnancy Study
A recent UK multicenter trial found that hybrid closed-loop insulin therapy significantly improved glycemic control in pregnant women with Type 1 diabetes. Participants using the closed-loop system maintained target glucose levels 68.2% of the time, compared to 55.6% for standard therapy, with less hyperglycemia and lower glycated hemoglobin levels. No major safety issues were reported. These encouraging results highlight the potential of hybrid closed-loop systems to enhance maternal health during pregnancy.
Read the full study here.
Interpretation
Hybrid closed-loop insulin delivery proves to be a transformative approach, significantly enhancing glucose control while concurrently reducing the risk of hypoglycaemia across a wide age range of patients with suboptimally controlled Type 1 diabetes. Dana CamAPS® FX is revolutionising Type 1 diabetes management, offering a brighter, more stable future for those living with this condition.
For more information on Dana CamAPS® FX you can visit the Camdiabs website